No Data
No Data
With 61% Ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Boasts of Strong Institutional Backing
EyePoint: JPMorgan, Citigroup Among Managers for Offering >EYPT
EyePoint to Use Net Proceeds From Offering to Advance Clinical Development of Duravyu for Wet Age Related Macular Degeneration, Diabetic Macular Edema >EYPT
EyePoint Pharmaceuticals Grants Underwriters Option for Additional 1.9M Shares >EYPT
Scotiabank Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $18
EyePoint Pharmaceuticals Is Maintained at Buy by Chardan Capital
No Data
No Data